文献速递肺外科

肺段切除术与肺叶切除术在代谢增高的临床IA期肺腺癌中效果相当

Segmentectomy Is Equivalent to Lobectomy in Hypermetabolic Clinical Stage IA Lung Adenocarcinomas.
PubMed 文献 · Ann Thorac Surg · 2018-09-19

本研究基于前瞻性数据库,纳入2000至2016年接受肺叶或肺段切除的临床IA期高代谢(SUVmax≥3g/dL)肺腺癌患者414例,经倾向匹配(4:1)后肺叶组156例、肺段组46例。结果显示两组5年无复发生存率和癌症特异性生存率无显著差异,但肺叶组淋巴结清扫更彻底。

要点

  • 高代谢临床IA期肺腺癌中,肺段切除与肺叶切除的5年无复发生存率(72% vs 69%)和癌症特异性生存率(92% vs 83%)无显著差异。
  • 肺叶组病理淋巴结升级率17% vs 肺段组7%(p=0.085),病理升级率38% vs 26%(p=0.143),均未达统计学显著。
  • 肺叶组切除淋巴结中位数14枚 vs 肺段组7枚(p<0.001),但未转化为生存获益。

核心结论

  • 对于经仔细分期的cT1 N0高代谢(SUVmax≥3g/dL)肺腺癌,肺叶切除与肺段切除是肿瘤学效果相当的手术方式。
  • 尽管肺叶切除与更彻底的淋巴结清扫相关,但 compared with 肺段切除并未转化为更高的无复发生存率或癌症特异性生存率。

研究设计与样本

  • 回顾性查询前瞻性收集的数据库,纳入2000至2016年接受肺叶或肺段切除的临床IA期高代谢(SUVmax≥3g/dL)肺腺癌患者。
  • 共414例高代谢肿瘤患者接受肺叶或肺段切除,经倾向匹配(4:1)后肺叶组156例、肺段组46例。

主要发现

  • 肺叶组病理淋巴结升级率17% vs 肺段组7%(p=0.085),病理升级率38% vs 26%(p=0.143),均未达统计学显著。
  • 肺叶组切除淋巴结中位数14枚 vs 肺段组7枚(p<0.001)。
  • 肺叶组 vs 肺段组5年无复发生存率72% vs 69%(p=0.679),5年癌症特异性生存率92% vs 83%(p=0.557),均无显著差异。

关键数值与推荐

  • 高代谢肿瘤定义为最大标准摄取值(SUVmax)≥3g/dL。
  • 倾向匹配比例为4:1(肺叶:肺段)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent studies have suggested that lobectomy and segmentectomy hold equivalent oncologic outcomes, particularly for small, peripheral, subsolid nodules. However, for hypermetabolic nodules that are frequently associated with high rates of nodal disease, recurrence, or mortality, the optimum oncologic procedure was not assessed. We hypothesize that for hypermetabolic, cT1 N0 adenocarcinoma, lobectomy and segmentectomy are associated with comparable outcomes. METHODS: A prospectively collected database was queried for patients with clinical stage IA lung adenocarcinoma who underwent lobectomy or segmentectomy (2000 to 2016) for hypermetabolic tumors (maximum standard uptake value [SUVmax] ≥ 3g/dL). To obtain balanced groups of patients, a propensity matching analysis was done. RESULTS: A total of 414 patients had hypermetabolic tumors and underwent lobectomy or segmentectomy. Patients were propensity matched (4:1) (lobectomy: n = 156, segmentectomy: n = 46). Patients in the lobectomy group had a higher rate of pathologic nodal upstaging (17% versus 7%, p = 0.085) and a higher pathologic upstaging rate (38% versus 26%, p = 0.143) than the segmentectomy group. In addition, the lobectomy group had a higher number of resected lymph nodes than the segmentectomy group (median lymph nodes resected: 14 versus 7, p < 0.001). No differences were found in in 5-year recurrence-free survival (RFS; 72% versus 69%, p = 0.679) or in 5-year cancer-specific survival (CSS; 92% versus 83%, p = 0.557) between patients who underwent lobectomy or segmentectomy, respectively. CONCLUSIONS: Our data show that lobectomy and segmentectomy are comparable oncologic procedures for patients with carefully staged cT1 N0 lung adenocarcinoma with hypermetabolic tumors (SUVmax ≥ 3g/dL). Although lobectomy was associated with a more thorough lymph node dissection, this did not translate into a higher rate of RFS or CSS compared with segmentectomy.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Kamel MK, Rahouma M, Lee B, et al. Segmentectomy Is Equivalent to Lobectomy in Hypermetabolic Clinical Stage IA Lung Adenocarcinomas. Ann Thorac Surg. 2018. PMID: 30240764. doi:10.1016/j.athoracsur.2018.07.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。